Clinical trial
A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women
NCT02210689 is registered in ClinicalTrials.gov with Actavis Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women
- Lead sponsor
- Actavis Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2014
- Completion date
- December 31, 2014
- Enrollment
- 604 (actual)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.
bacterial vaginosis, signs and symptoms to be evaluated and recorded include, vaginal discharge color, odor, and consistency, vulvovaginal inflammation (objective) absent, mild, moderate, or severe, vulvovaginal itching and irritation (subjective) absent, mild, moderate, or severe